Advertisement
Advertisement

Read Now: News and Research From ICAAC 2014

Medical News

Merck's HIV Drug Isentress Fails Once-a-Day Study

December 1, 2010

Taking the HIV drug Isentress once a day is not as effective as the standard twice-daily regimen, reported drug manufacturer Merck & Co. Based on these initial results, Merck is suspending the Phase III trial of once-daily dosing.

Isentress is the only HIV drug that works by blocking integrase, an enzyme that allows HIV to insert its genetic material into human DNA. Taken twice a day, Isentress is used among both previously treated and treatment-naive HIV patients.

The trial enrolled 775 patients who were taking other HIV medications in addition to Isentress. One subset received 800 milligrams of Isentress once-daily, another group received the standard 400-milligram dose twice per day.

After 48 weeks, HIV was lowered to undetectable levels in 83.2 percent of patients on the once-daily regimen and 88.9 percent of patients on the twice-daily schedule.

Back to other news for December 2010




 
See Also
Once-Daily Raltegravir "Not Non-Inferior" to Twice-Daily

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement